Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-01-27

FDA Approved: DICLOFENAC SODIUM — Original Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved diclofenac sodium topical gel, 1%, under an Original Application (ANDA) by BluePoint Laboratories for relief of osteoarthritis pain in joints.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • diclofenac sodium topical gel, 1% (diclofenac sodium topical gel, 1%)

Snippet

ORIG AP for DICLOFENAC SODIUM (DICLOFENAC SODIUM TOPICAL GEL, 1%)